NEW YORK (GenomeWeb News) – Investment bank UBS yesterday upgraded Cepheid’s shares from “Neutral” to “Buy” based on the current valuation of the stock.
 
Analyst Derik De Bruin noted in a research note that Cepheid’s stock is down 40 percent from its peak of $32.83 in late January and February, “due in part to insider selling, conflicting views on the importance of universal MRSA testing in the medical literature, and reimbursement confusion.” He wrote that the stock’s current valuation is “compelling.”
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.